Engineered immune cells called CAR-T cells are used in the treatment of cancer. Researchers from Uppsala University have now ...

The FDA has granted approval for Celltrion's Avtozma in both IV and SC formulations as Actemra biosimilar for treating ...

In his 2025 to 2026 term as American Academy of Allergy, Asthma & Immunology president, Frank S. Virant, MD, FAAAAI, plans to ...

A new antibody therapy effectively protects monkeys from severe H5N1 avian flu, offering hope for a universal flu vaccine and ...

At the heart of Natural Pearl is the Golden Youth product featuring Marinoplex™—a proprietary ingredient developed through ...

We recently compiled a list of the 10 Most Promising Dividend Stocks According to Hedge Funds. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...

Q4 2024 Earnings Call Transcript January 31, 2025 AbbVie Inc. misses on earnings expectations. Reported EPS is $2.16 EPS, expectations were $2.98. Operator: Good morning and thank you for standing by.

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of a public offering of an ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...

AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...

Five years after SARS-CoV-2 first surfaced in Wuhan, China, researchers are still trying to understand long COVID. In this ...